The Hereditary Cancer Programme promotes research from a multidisciplinary perspective in order to guarantee timely healthcare quality. It places emphasis on:
- Improvement of diagnostic algorithms, combining DNA-, RNA- and protein-level testing using latest-generation technology, and in the implementation of functional clinical trials.
- Identification of new biomarkers that allow risk to be individualised in order to personalise treatment and know the molecular basis of the phenotypic variability.
- Assessment of the genotype/phenotype correlation in hereditary colorectal cancer and in hereditary breast and ovarian cancer.
- Development and implementation of interventions in the genetic counselling process that improve the quality of life of patients, placing emphasis on how patients assimilate genetic information and the associated risk, identifying markers of post-traumatic growth.
- Promotion of the development and assessment of new therapeutic approaches specific to this type of disease, with special interest in chemoprevention strategies.
- Development of joint projects with the Cancer Registry of Girona that are aimed at relating epidemiology with hereditary cancer.
This work is not done alone, and we actively take part in national and international consortia that have as their objective to better understand hereditary cancer and to assess the efficacy of new treatment or monitoring measures.